Tempest Therapeutics Net Income Over Time
| TPST Stock | USD 2.36 0.05 2.16% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tempest Therapeutics Performance and Tempest Therapeutics Correlation. Is there potential for Biotechnology market expansion? Will Tempest introduce new products? Factors like these will boost the valuation of Tempest Therapeutics. If investors know Tempest will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Tempest Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Tempest Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Tempest Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Tempest Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Tempest Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tempest Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Tempest Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Tempest Therapeutics and related stocks such as OnKure Therapeutics, Kezar Life Sciences, and FibroGen Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OKUR | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (39.8 M) | (29.5 M) | (35.3 M) | (52.7 M) | (47.4 M) | (49.8 M) |
| KZR | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (8.5 M) | (23.2 M) | (31.5 M) | (39 M) | (54.6 M) | (65.3 M) | (101.9 M) | (83.7 M) | (75.4 M) | (71.6 M) |
| ALGS | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (52.3 M) | (108.5 M) | (128.3 M) | (96 M) | (87.7 M) | (131.2 M) | (118.1 M) | (124 M) |
| MRSN | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (13.7 M) | (38.7 M) | (64.3 M) | (28.2 M) | (88 M) | (170.1 M) | (204.2 M) | (171.7 M) | (69.2 M) | (62.3 M) | (65.4 M) |
| XLO | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (55.2 M) | (74.3 M) | (87.3 M) | (76.4 M) | (58.2 M) | (52.4 M) | (55 M) |
| PDSB | (4.7 M) | (4.7 M) | (4.7 M) | (6.9 M) | (12.2 M) | (28.1 M) | (38.8 M) | (50.9 M) | (40.9 M) | (7 M) | (14.8 M) | (16.9 M) | (40.9 M) | (42.9 M) | (37.6 M) | (33.8 M) | (35.5 M) |
| ATNM | (18.4 K) | 10.3 K | (8.4 M) | (10.8 M) | (24.7 M) | (21 M) | (24.3 M) | (26.6 M) | (23.7 M) | (21.9 M) | (22.2 M) | (24.8 M) | (33 M) | (48.8 M) | (38.2 M) | (34.4 M) | (32.7 M) |
| BRNS | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (17.7 M) | (50.9 M) | 5.3 M | (73.3 M) | (61.1 M) | (55 M) | (57.7 M) |
| INMB | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (277 K) | (831 K) | (12.4 M) | (7.7 M) | (12.1 M) | (30.3 M) | (28.6 M) | (30 M) | (42.1 M) | (37.9 M) | (36 M) |
Tempest Therapeutics and related stocks such as OnKure Therapeutics, Kezar Life Sciences, and FibroGen Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Tempest Therapeutics financial statement analysis. It represents the amount of money remaining after all of Tempest Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Tempest Therapeutics | TPST |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2000 Sierra Point |
| Exchange | NASDAQ Exchange |
USD 2.36
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.